BiBo Pharma successfully passed the EU QP audit and entered the European market


On October 22, 2022, after nearly 10 months of careful preparation and unremitting efforts, the P02 production site of BiBo Pharma which located in Lingang Blue Bay has successfully completed the EU QP on-site audit.

The audit has no serious defects (Critical, 0) and no major defects (Major, 0). The results will enable the company to proceed at full speed with the European market filing program it is serving.


From October 24th to 26th, 2022, the BIO-European Biopharmaceuticals Annual Conference (BIO-Europe) was held in Leipzig, Germany. The Boston team of BiBo Pharma set up a booth to participate in the exhibition, fully launching BiBo Pharma’s European market development.

BIO-Europe is Europe’s premier biopharmaceutical cooperation event. Investors from all over the world, executives from leading global biotechnology companies, business development teams from large and medium-sized pharmaceutical companies, and biopharmaceutical supply chain service providers gather together to work together. Explore industry development trends and seek opportunities for cooperation and development.

The world’s first 30,000 liter production base

At the same time, the construction of the BiBo P03 project in Lingang——the 30,000-liter large-scale commercial production base of BiBo Biotechnology, is also actively launching. It is expected that the hoisting ceremony of the 30,000-liter stainless steel bioreactor will be held in November. This is the first 30,000-liter reactor in the world, and the volume of a single tank is the largest in the world. At present, BiBo P03 has locked the first overseas production order based on 30,000 liters of production capacity, and will be put into commercial production in the second half of 2023.